🇬🇧 Krtin Nithiyanandam

The morning Krtin Nithiyanandam walked into his school laboratory in Surrey with a notebook full of antibody diagrams, he was fifteen years old — and he was already thinking about how to defeat one of the most devastating diseases in the history of human medicine. Alzheimer's disease, the slow erasure of memory and self that afflicts more than fifty million people worldwide, had long resisted early detection. By the time a patient received a diagnosis, years of neurological damage had already accumulated, making treatment exponentially harder. Krtin had read enough to understand the problem. What struck him, with the clarity that sometimes only young minds possess, was that nobody had yet tried to cross the blood-brain barrier with a molecule designed specifically to search and illuminate.

Born on 20 June 2000 in Chennai, India, Krtin moved to Britain with his family in early childhood and grew up in Surrey. His interest in medicine was not abstract. As a young child, he had suffered from hearing impairment, an experience that gave him an unusually personal understanding of what it means to live inside a malfunctioning body — and what it would mean to receive an early warning rather than a late diagnosis. By the time he entered Sutton Grammar School, he had already begun to think about biology not as a collection of facts to be memorized but as an engineering problem to be solved.

The solution he proposed was audacious in its simplicity. Working largely independently, Krtin designed a bispecific antibody — a molecule composed of two different fragments, each performing a distinct function. One fragment was derived from an anti-oligomeric amyloid beta antibody, targeting the toxic protein clusters that appear in the brain years before Alzheimer's symptoms emerge. The other was derived from an anti-transferrin receptor antibody — the key to the Trojan horse mechanism that allowed his molecule to cross the blood-brain barrier by mimicking a protein the brain naturally welcomes. To make the molecule visible on brain scans, he conjugated it to a quantum dot capable of emitting light detectable by both MRI and near-infrared imaging. The result, at least in his theoretical model, was a diagnostic tool that could identify Alzheimer's disease a decade or more before a patient experienced any cognitive decline.

He entered this work in the 2015 Google Science Fair, the world's largest online science competition for students between thirteen and eighteen. The judges were scientists and researchers from Google, LEGO, National Geographic, Virgin Galactic, and Scientific American. They had seen thousands of entries. Krtin's work earned him the Scientific American Innovator Award — one of the fair's most prestigious prizes — along with a $25,000 scholarship. At fifteen, he had produced research sophisticated enough to earn the respect of professional scientists.

The recognition transformed his platform without transforming his focus. In the years that followed, he addressed audiences at TEDxLondon, TEDxGateway, WIRED Next Generation, and the Royal Society of Medicine, explaining his research and advocating for greater student participation in scientific inquiry. He simultaneously pursued a second project: developing a novel siRNA mechanism to decrease ID4 expression in aggressive triple-negative breast cancers, a form of the disease with among the worst prognoses and fewest treatment options. In 2017, The Observer named him a Rising Star in Science, and TIME magazine included him on its 30 Most Influential Teens list.

What distinguishes Krtin's story is not merely precocity — the scientific landscape has always produced the occasional brilliant teenager. What distinguishes it is the quality of the problem he chose and the rigour with which he approached it. Alzheimer's research is among the most difficult and most important fields in biomedicine. The failure rate for clinical trials targeting the disease approaches ninety-nine percent. Every year, the global cost of dementia care exceeds a trillion dollars. A test that could identify the disease years before symptoms appear would not merely be a scientific achievement. It would rewrite the economics of dementia care and give millions of patients the one thing current medicine cannot offer them: time.

Krtin Nithiyanandam is not the first person to imagine solving Alzheimer's. He is, however, among the very few fifteen-year-olds who sat down and built a molecular architecture to try. That combination of ambition, rigour, and genuine scientific creativity — assembled in a grammar school lab in Surrey — is what places him among the most compelling scientific minds of his generation.